Milestone Pharmaceuticals: Selling The News On Cardamyst Approval Makes No Sense [Seeking Alpha]
Milestone announces acceptance of MAA by EMA for etripamil nasal spray [Yahoo! Finance]
Milestone Pharmaceuticals (NASDAQ:MIST) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
Milestone Pharmaceuticals Announces Acceptance of Marketing Authorization Application for Etripamil Nasal Spray in PSVT by the European Medicines Agency
Milestone Pharmaceuticals (NASDAQ:MIST) was upgraded by analysts at
Wall